Stan Micek - Spectral Interim Officer
| MDAI Stock | 1.19 0.05 4.39% |
Executive
Stan Micek is Interim Officer of Spectral AI
| Address | 2515 McKinney Avenue, Dallas, TX, United States, 75201 |
| Phone | 972-499-4934 |
| Web | https://www.spectral-ai.com |
Spectral Management Efficiency
The company has return on total asset (ROA) of (0.4387) % which means that it has lost $0.4387 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (23.0832) %, meaning that it created substantial loss on money invested by shareholders. Spectral's management efficiency ratios could be used to measure how well Spectral manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Spectral's Return On Capital Employed is increasing as compared to previous years. The Spectral's current Return On Equity is estimated to increase to 12.81, while Return On Tangible Assets are forecasted to increase to (1.85). As of now, Spectral's Total Assets are increasing as compared to previous years. The Spectral's current Non Currrent Assets Other is estimated to increase to about 341.7 K, while Net Tangible Assets are projected to decrease to under 9.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Justin McCue | Tscan Therapeutics | N/A | |
| Thomas McDuffie | Jacobs Solutions | 75 | |
| Emilie Desodt | Genfit | 41 | |
| Robert Duff | Jacobs Solutions | 65 | |
| Meriam Kabbaj | Genfit | 50 | |
| Patrice Baumann | Enersys | N/A | |
| Shannon Thomas | Enersys | N/A | |
| Ayan Banerjee | Jacobs Solutions | N/A | |
| Jonathan CFA | Jacobs Solutions | N/A | |
| Shelette Gustafson | Jacobs Solutions | 59 | |
| Stephen Arnette | Jacobs Solutions | 56 | |
| Stefanie JD | Genfit | 42 | |
| Heather Savelle | Tscan Therapeutics | N/A | |
| Cagan Gurer | Tscan Therapeutics | N/A | |
| Madhuri Andrews | Jacobs Solutions | 57 | |
| Ray MBA | Tscan Therapeutics | N/A | |
| Ann Hargraves | Tscan Therapeutics | N/A | |
| Debora MD | Tscan Therapeutics | 48 | |
| Philipp Michalsky | Enersys | N/A | |
| Zoran JD | Tscan Therapeutics | 54 | |
| William Birkhofer | Jacobs Solutions | 76 | |
Management Performance
| Return On Equity | -23.08 | ||||
| Return On Asset | -0.44 |
Spectral AI Leadership Team
Elected by the shareholders, the Spectral's board of directors comprises two types of representatives: Spectral inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectral. The board's role is to monitor Spectral's management team and ensure that shareholders' interests are well served. Spectral's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectral's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stan Micek, Interim Officer | ||
| Erich Spangenberg, CEO Director | ||
| Jeffrey Thatcher, Chief Scientist | ||
| Vincent Capone, General Secretary | ||
| Christine Marks, Vice Commercialization | ||
| David Bronson, Financial Controller | ||
| Niko Pagoulatos, Chief Officer | ||
| Pr Chadwick, Executive EMEA | ||
| John MD, Founder Chairman | ||
| Wensheng Fan, Chief CoFounder | ||
| MD FACS, Chief Consultant | ||
| Peter CPA, Chief Officer | ||
| Jeremiah MBA, Chief Officer |
Spectral Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectral a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.08 | ||||
| Return On Asset | -0.44 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 26.47 M | ||||
| Shares Outstanding | 18.59 M | ||||
| Shares Owned By Insiders | 42.18 % | ||||
| Shares Owned By Institutions | 20.74 % | ||||
| Number Of Shares Shorted | 915.66 K | ||||
| Price To Book | 29.88 X |
Currently Active Assets on Macroaxis
When determining whether Spectral AI is a strong investment it is important to analyze Spectral's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spectral's future performance. For an informed investment choice regarding Spectral Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Spectral AI. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectral. If investors know Spectral will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectral listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Revenue Per Share 1.6 | Quarterly Revenue Growth 1.376 | Return On Assets (0.44) | Return On Equity (23.08) |
The market value of Spectral AI is measured differently than its book value, which is the value of Spectral that is recorded on the company's balance sheet. Investors also form their own opinion of Spectral's value that differs from its market value or its book value, called intrinsic value, which is Spectral's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectral's market value can be influenced by many factors that don't directly affect Spectral's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectral's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectral is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectral's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.